Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration

• Published in: Acta pharmacologica Sinica 2016-02, Vol.37 (2), p.276-284
• Main Authors: Wang, Hong-yun, Chen, Xia, Jiang, Ji, Shi, Jun, Hu, Pei
• Format: Article
• Language: English
• Subjects: Administration, Oral; Adult; Aged; Aged, 80 and over; Asian People; Biomedical and Life Sciences; Biomedicine; Computer Simulation; Cytochrome P-450 CYP3A - metabolism; Female; Humans; Hypnotics and Sedatives - administration & dosage; Hypnotics and Sedatives - blood; Hypnotics and Sedatives - metabolism; Hypnotics and Sedatives - pharmacokinetics; Immunology; Internal Medicine; Male; Medical Microbiology; Midazolam - administration & dosage; Midazolam - blood; Midazolam - metabolism; Midazolam - pharmacokinetics; Middle Aged; Models, Biological; Original; original-article; Pharmacology/Toxicology; Vaccine; Young Adult; 制剂; 处方; 药学; 药理
• ISSN: 1671-4083; 1745-7254
• DOI: 10.1038/aps.2015.122

Aim： To evaluate the SimCYP simulator ethnicity-specific population model for predicting the pharmacokinetics of midazolam, a typical CYP3A4/5 substrate, in Chinese after oral administration. Methods： The physiologically based pharmacokinetic （PBPK） model for midazolam was developed using a SimCYP population-based simulator incorporating Chinese population demographic, physiological and enzyme data. A clinical trial was conducted in 40 Chinese subjects （the half was females） receiving a single oral dose of 15 mg midazolam. The subjects were separated into 4 groups based on age （20-50, 51-65, 66-75, and above 76 years）, and the pharmacokinetics profiles of each age- and gender-group were determined and the results were used to verify the PBPK model. Results： Following oral administration, the simulated profiles of midazolam plasma concentrations over time in virtual Chinese were in good agreement with the observed profiles, as were AUC and Cmax. Moreover, for subjects of varying ages （20-80 years）, the ratios of predicted to observed clearances were between 0.86 and 1.12. Conclusion： The SimCYP PBPK model accurately predicted the pharmacokinetics of midazolam in Chinese from youth to old age. This study may provide novel insight into the prediction of CYP3A4/5-mediated pharmacokinetics in the Chinese population relative to Caucasians and other ethnic groups, which can support the rational design of bridging clinical trials.